NVTA News and Press, Invitae Corporation From 03/16/23

Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology PR Newswire – Expert in the field of gastrointestinal cancer and precision oncology to lead Invitae's medical oncology team with a particular focus on somatic testing development – ...

Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing PR Newswire – New research looking at underrepresented racial, ethnic and ancestry groups underscores the importance of universal germline genetic tes...

2023-03-13 12:42:06 ET Are you looking for penny stocks to buy and wondering where to begin? You could hit the list of popular stocks with news. That may or may not give you a list of quality stocks. You could also look for technical signals, including penny stocks with high volume or i...

2023-03-07 08:20:43 ET Summary Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to address its convertible debt deal, fully repaid its sen...

2023-03-06 16:05:02 ET Invitae Corporation (NVTA) TD Cowen 43rd Annual Health Care Conference Transcript March 6, 2023, 1:30 PM ET Executives Ken Knight - President and CEO Roxi Wen - Chief Financial Officer Analysts Dan Brennan - Cowen and Company ...

Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage PR Newswire – Blue Shield of California has over 3 million covered members in CA – SAN FRANCISCO , March 6, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA...

Summary Exact Sciences is shifting its focus towards achieving positive adjusted EBITDA as a way to signal a path to eliminate cash burn. The company's long-term prospects look interesting with a pipeline spread across different timelines, including a MCED test and MRD testing. Whil...

Invitae to Present at the TD Cowen 43rd Annual Health Care Conference PR Newswire SAN FRANCISCO , March 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight , president and chief executive officer, ...

Invitae Corp. ( NYSE: NVTA ) is off 23% in Wednesday afternoon trading after issuing lackluster guidance and signing exchange and financing agreements with Deerfield Management Company. The medical genetics company said it expects 2023 revenue of "over $500M," which represents lo...

Summary Invitae announces debt transaction to refinance 2024 notes. Q4 results decent as ongoing restructuring continues. 2023 guidance could have been better. After the bell on Tuesday, we received fourth quarter results from genetics company Invitae ( NVTA ). Sha...